Most Read Articles
Audrey Abella, 21 Dec 2020
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.

Prasugrel superior to ticagrelor in reducing risk of death, MI, stroke in NSTE-ACS patients

27 Nov 2020

Prasugrel appears to do better than ticagrelor in attenuating the combined 1-year risk of death, myocardial infarction (MI), and stroke without increasing bleeding risk in patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), a recent study has shown.

“Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina or NSTEMI,” the authors said.

This posthoc analysis combined the prespecified subgroups of unstable angina and NSTEMI from the randomized ISAR-REACT 5 trial. A total of 1,179 patients assigned to ticagrelor and 1,186 to prasugrel were included in the study. Ticagrelor was initiated immediately after randomization and prasugrel after coronary angiography.

The primary endpoint of a composite of death, MI, or stroke during 1-year follow-up occurred in 101 (8.7 percent) patients in the ticagrelor group and in 73 (7.3 percent) in the prasugrel group (hazard ratio [HR], 1.41, 95 percent confidence interval [CI], 1.04–1.90). The HRs for all-cause death and MI were 1.43 (95 percent CI, 0.93–2.21) and 1.43 (95 percent CI, 0.94–2.19), respectively.

The safety endpoint of Bleeding Academic Research Consortium class 3–5 was reached in 49 (5.2 percent) patients in the ticagrelor group and in 41 (4.7 percent) in the prasugrel group (HR, 1.09, 95 percent CI, 0.72–1.65).

The efficacy advantage with prasugrel persisted after the first month in landmark analysis.

Due to the posthoc design of the analysis, further research is warranted to confirm these findings, the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 21 Dec 2020
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.